Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
October 04, 2022 08:45 ET
|
Immunovant
NEW YORK, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
September 28, 2022 10:45 ET
|
Immunovant
In animal studies, deep IgG lowering similar to batoclimab with no or minimal impact on albumin and low-density lipoprotein (LDL) was observed. Plan to submit IND and initiate Phase 1 study in early...
Immunovant to Present at Roivant Investor Day on September 28th
September 21, 2022 08:00 ET
|
Immunovant
NEW YORK, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
September 09, 2022 08:00 ET
|
Immunovant
NEW YORK, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today...
UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab
September 07, 2022 07:11 ET
|
Immunovant
Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first...
Immunovant Announces Two New Development Programs for Batoclimab
September 07, 2022 06:30 ET
|
Immunovant
Plan to initiate a Pivotal Phase 2b trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in the second half of 20221 with initial results from open-label period 1 expected in the first...
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
August 24, 2022 08:00 ET
|
Immunovant
NEW YORK, Aug. 24, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will...
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022
August 05, 2022 07:00 ET
|
Immunovant
NEW YORK, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
June 08, 2022 07:00 ET
|
Immunovant
Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in...
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
June 06, 2022 16:47 ET
|
Immunovant
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...